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Discovery of BACE1, the Alzheimer’s β-secretase
Autosomal dominant mutations in the genes for amyloid 
precursor protein (APP) and the presenilins (presenilin-1 
and presenilin-2) cause familial Alzheimer’s disease (AD) 
(reviewed in [1]), and these ﬁ  ndings together with others 
suggest that the amyloid-beta (Aβ) peptide plays a central 
role in AD pathogenesis. Consequently, therapeutic 
approaches to lower brain Aβ levels should be eﬃ   cacious 
for the treatment or prevention of AD. Aβ is generated 
through the sequential endoproteolysis of APP by the 
β-secretase and γ-secretase enzymes (reviewed in [2]). 
β-secretase cuts ﬁ  rst at the N-terminus of Aβ; γ-secretase 
cleaves only thereafter to make the C-terminus of Aβ. 
Th  en Aβ is secreted from neurons to form amyloid 
plaques in the AD brain. Inhibition of β-secretase should 
thus decrease production of Aβ, the pathogenic form of 
the peptide.
Since the discovery of Aβ, the molecular identity of the 
β-secretase has been intensely sought because of its 
prime status as a drug target for AD. Prior to the 
enzyme’s discovery, the properties of β-secretase activity 
in cells and tissues had been extensively characterized. In 
1999 ﬁ  ve groups reported the molecular cloning of the 
β-secretase [3], variously naming the enzyme BACE [4], 
Asp2 [5,6], or memapsin 2 [7] (herein, β-secretase will be 
referred to as β-site amyloid precursor protein cleaving 
enzyme 1 (BACE1)). Th   e groups used diﬀ  erent isolation 
methods (expression cloning, protein puriﬁ  cation, 
genomics), yet all identiﬁ  ed the same enzyme and agreed 
it possessed all the characteristics of β-secretase.
BACE1 cell biology
BACE1 is a type 1 transmembrane aspartic protease 
related to the pepsins and retroviral aspartic proteases 
[3-7]. BACE1 activity has a low optimum pH [4], and the 
enzyme is predominantly localized in acidic intracellular 
compartments (for example, endosomes, trans-Golgi) 
with its active site in the lumen of the vesicle [3-8]. Th  e 
highest expression levels of BACE1 are found in neurons 
[3,4]. Importantly, BACE1 overexpression or BACE1 
knockdown increases or decreases production of Aβ and 
β-secretase-cleaved APP fragments, respectively [4]. In 
addition, the activity of BACE1 on wild-type and mutant 
APP substrates is consistent with the sequence speciﬁ  city 
of β-secretase. For example, BACE1 cleaves APP with the 
Swedish familial AD-causing mutation (APPswe) 
~10-fold to 100-fold more eﬃ   ciently than wild-type APP 
[3,4,9].
BACE1 is synthesized as a 501-amino-acid zymogen 
(containing a short prodomain) in the endoplasmic 
reticulum [3-7,10]. Within the lumen of the endoplasmic 
reticulum, BACE1 is subjected to simple glycosylation on 
four Asn residues [11] and transient acetylation on seven 
Arg residues [12]. Further addition of complex carbo-
hydrates and removal of the BACE1 prodomain by furin 
convertases occur in the Golgi compartment [13-16]. 
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phorylation together with a C-terminal acidic cluster di-
leucine motif (DXXLL) regulates BACE1 recycling between 
the cell surface and endosomal compartments [17-19].
BACE1 is S-palmitoylated on four Cys residues located 
at the junction of the transmembrane and cytosolic 
domains [15,20], and this modiﬁ  cation facilitates BACE1 
partitioning into lipid rafts. Increased targeting of BACE1 
to the lipid raft was suggested to enhance β-secretase 
processing of APP [21,22]. A recent study, however, 
reported that nonraft-localized palmitoylation-deﬁ  cient 
BACE1 is equally active in APP processing and Aβ 
secretion as is raft-associated palmitoylated BACE1 [20]. 
Although BACE1 can process APP in both raft and non-
raft environments, a membrane-anchored version of a 
BACE1 transition-state inhibitor produced by linkage to 
a sterol moiety appeared more potent as a result of 
targeting to lipid rafts [23].
Golgi-localized γ-ear-containing ARF-binding (GGA) 
proteins interact with the BACE1 C-terminal DXXLL 
motif via a VHL domain and regulate traﬃ   cking  of 
BACE1 between the late Golgi and early endosomes 
[24-26]. Depletion of GGA proteins by RNAi or disrup-
tion of phosphorylation of BACE1 on Ser498 increases 
accumu  lation of BACE1 in early endosomes, an acidic 
environ  ment that favors BACE1 cleavage of APP and 
subsequent Aβ production [27-29]. Interestingly, GGA3 is 
a caspase-3 substrate and is degraded during neuronal 
apop  tosis. In the brains of AD patients, in which neuronal 
apoptosis may occur, the levels of GGA3 are signiﬁ  cantly 
decreased [28]. Reduced GGA3 levels not only increase 
localization of BACE1 to early endosomes, but also 
stabilize BACE1 by preventing its traﬃ   cking to lysosomes 
where it is degraded.
Intracellular localization of BACE1 can be altered by 
other regulatory factors in addition to the GGA proteins. 
Reticulon/Nogo family members have been identiﬁ  ed as 
negative regulators of BACE1 [30,31]. Overexpression of 
reticulon proteins results in prolonged BACE1 retention 
in the endoplasmic reticulum with concomitant decrease 
in BACE1-mediated APP cleavage [32]. Sorting nexin 6 is 
another BACE1-associated protein that inﬂ  uences BACE1 
subcellular localization and acts as a negative regulator of 
BACE1 activity [33]. Inhibition of sorting nexin  6 
increases Aβ as well as retrograde transport of BACE1 to 
the trans-Golgi network. Sortilin is the most recently 
identiﬁ   ed modulator of BACE1 traﬃ   cking [34]. When 
overexpressed, sortilin increases BACE1-mediated APP 
cleavage, while RNAi-mediated knockdown decreases Aβ. 
Future studies aimed at identifying the BACE1 inter-
actome will yield fruitful information regarding novel 
proteins that control BACE1 traﬃ   cking, and hence Aβ 
production, which in turn could represent potential AD 
therapeutic targets.
In vivo validation of BACE1
Soon after BACE1 was discovered, its homolog BACE2 
was identiﬁ   ed [5,35]. BACE1 and BACE2 shared 64% 
amino acid sequence similarity, which suggested BACE2 
was also a β-secretase. BACE2 was expressed at low 
levels in neurons and did not have the same cleavage 
activity as β-secretase, however, indicating it was a poor 
β-secretase candidate. To demonstrate that BACE1 was 
the β-secretase in vivo, BACE–/– mice were generated [36-
39]. Initial reports indicated that BACE1–/– mice were 
viable and fertile, suggesting that therapeutic inhibition 
of BACE1 might be free of mechanism-based side eﬀ  ects. 
Recent studies, however, have shown that BACE1–/– mice 
are not completely normal (discussed below).
Importantly, Aβ production, amyloid pathology, electro-
physiological dysfunction, and cognitive deﬁ  cits  were 
prevented when BACE1–/– mice were bred to APP trans-
genic mice [36,40-43]. Moreover, lentiviral delivery of 
BACE1 RNAi attenuated Aβ amyloidosis and cognitive 
deﬁ  cits in APP transgenics [43,44]. Th   ese results demon-
strated that BACE1 is the major, if not only, β-secretase 
enzyme in the brain. Taken together, BACE1 characteri-
zation and validation studies have unequivocally demon-
strated that BACE1 is the authentic β-secretase in the 
brain and that it is a promising therapeutic target for 
lowering cerebral Aβ levels.
BACE1 substrates
In addition to APP, BACE1 has other substrates (Table 1), 
and identiﬁ  cation of these substrates is useful not only 
for evaluation of potential mechanism-based toxicity 
arising from inhibition of BACE1 but also for designing 
potent and selective BACE1 inhibitors. Moreover, the 
diverse list of BACE1 substrates suggests a variety of 
BACE1 physiological functions.
All known BACE1 substrates are transmembrane 
proteins, such as Golgi-localized membrane-bound α2,6-
sialyltransferase [45,46], IL-1 type II receptor [47], P-
selectin glycoprotein ligand-1 [48], APP homologs Aβ 
precursor-like protein-1 and Aβ precursor-like protein-2 
[49-51], low-density lipoprotein receptor-related protein 
[51,52], the voltage-gated sodium channel β1 to β4 sub-
units [53-55], neuregulin-1 [56,57] and neuregulin-3 [58]. 
Recently, an un  biased screen for novel BACE1 substrates 
identiﬁ   ed 64 type I transmembrane proteins, three 
glycophos  pha  tidyl  inositol-linked proteins and one type II 
transmembrane protein [51]. Although the majority of 
these putative BACE1 substrates have not been validated, 
several were found to be cleaved by BACE1 in cell 
culture, including ephrin type A receptor 5, Golgi phos-
pho  protein-4, leucine-rich repeats and immunoglobulin-
like domain protein-2 (and -3), insulin-like growth factor 
2 receptor and semaphorin-4C. Further studies will be 
required to determine whether these proteins are BACE1 
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BACE1 substrates are likely to be discovered in the 
future.
BACE1 as a therapeutic target for Alzheimer’s 
disease
Although  BACE1–/– mice appear viable and fertile, the 
growing list of BACE1 substrates has suggested that less 
obvious phenotypes related to deﬁ  cient BACE1 proces-
sing of substrates may exist. Indeed, eliminating BACE1 
cleavage of neuregulin-1 in BACE1–/– mice causes 
reduced myelin sheath thickness of axons of both 
peripheral sciatic nerves [56,57] and central optic nerves 
[56]. BACE1–/– mice also display retarded remyelination 
of injured sciatic nerves [58]. In addition, recent studies 
have demonstrated that BACE1–/– mice exhibit increased 
frequency of spontaneous and kainite-induced seizures 
[59-61]. Hypomyelination and increased seizures ob-
served in BACE1–/– mice have raised concerns that 
therapeutic BACE1 inhibition may be associated with 
similar untoward eﬀ  ects in humans. However, whether 
the hypomyelination and seizure phenotypes in BACE1–/– 
mice are caused by the lack of BACE1 activity in the adult 
or during embryonic or postnatal development is 
currently unknown.
Because of potential adverse side eﬀ  ects  associated 
with strong inhibition or reduction of BACE1, investi-
gators have tested whether a moderate decrease in 
BACE1 activity would provide beneﬁ   ts in the central 
nervous system while limiting mechanism-based toxi-
cities. Laird and coworkers showed a signiﬁ  cant 
reduction of Aβ deposition in brains of 12-month-old 
APPswe;PS1DE9;BACE1+/– mice as compared with that of 
APPswe;PS1DE9;BACE1+/+ mice; however, no signiﬁ  cant 
diﬀ   erences were observed in brains of 20-month-old 
APPswe;PS1DE9;BACE1+/– animals [43]. It is unclear why 
the older mice in this study did not show reduced 
amyloidosis. In a similar study, McConlogue and 
colleagues reported a signiﬁ  cantly reduced Aβ burden in 
the brains of 13-month-old and 18-month-old 
PDAPP;BACE1+/– mice [62]. Although the two studies 
had diﬀ  erences, neither indicated a negative phenotype 
associated with the BACE1+/– mice. Taken together, these 
data suggest the exciting possibility that partial inhibition 
of BACE1 may eﬀ  ectively reduce Aβ deposition without 
mechanism-based toxicity.
BACE1 inhibitor development
Since the identiﬁ  cation of BACE1, intense eﬀ  orts have 
been underway to develop small-molecule BACE1 
inhibitors as drugs for AD. First-generation BACE1 
inhibitors were peptide-based mimetics (peptidomi-
metics) of the APP β-site that replaced the scissile amide 
bond with a nonhydrolizable transition state analog such 
as statine [3]. Th  e X-ray structure of BACE1 co-
crystallized with peptidomimetic inhibitors [63] greatly 
facilitated the rational design of BACE1 inhibitors. More 
recently, later-generation nonpeptidic compounds with 
low nanomolar half-maximal inhibitory concentration 
potencies have been generated (reviewed in [64-66]).
Although initial drug development eﬀ  orts  with 
peptidomimetic BACE1 inhibitors were encouraging, 
BACE1 has since proven to be a challenging medicinal 
chemistry target. Th   ere appear to be several reasons for 
this challenge. First, BACE1 has a large hydrophobic 
substrate-binding site designed to ﬁ  t polypeptides, thus 
making it diﬃ     cult to inhibit the enzyme with small 
nonpeptidic compounds that have desirable drug-like 
characteristics. Ideally, BACE1 inhibitor drugs should be 
of a molecular weight <500, orally bioavailable, meta-
bolically stable, intrin  sically potent, and highly selective 
for BACE1 over BACE2 and other aspartic proteases. 
Th   is latter point is relevant because BACE1–/–;BACE2–/– 
double knockout mice have enhanced postnatal lethality 
compared with BACE1–/– single knockout mice [39]. 
Compounds must also be hydrophobic enough to 
penetrate both plasma and intra  cellular membranes to 
gain access to the lumen of the compartment where the 
BACE1 active site is localized. Finally, eﬃ   cacious BACE1 
drugs would need to eﬃ   ciently cross the blood–brain 
Table 1. Validated BACE1 substrates and potential mechanism-based toxicity arising from BACE1 inhibition
Substrate Toxicity
APP, APLP1 and APLP2  Impaired cell–cell signaling, injury recovery, synaptic function, memory
IL1R2  Abnormal infl  ammatory response
LRP  Impairments in lipid metabolism, degradation of proteases and activation of lysosomal enzymes
Navβ1-4  Altered neuronal excitability [76]
Neuregulin-1 and neuregulin-3  Impaired remyelination following nerve injury [58]
PSGL-1  Altered leukocyte recruitment during innate and adaptive immune response [77]
ST6Gal I  Hepatopathology, B-cell dysfunction
APLP, amyloid beta precursor-like protein; APP, amyloid precursor protein; BACE1, β-site amyloid precursor protein cleaving enzyme 1; IL1R2, IL-1 type II receptor; LRP, 
low-density lipoprotein receptor-related protein; Navβ1–4, voltage-gated sodium channel β1 to β4 subunits; PSGL-1, P-selectin glycoprotein ligand-1; ST6Gal I, Golgi-
localized membrane-bound β-galactoside α2,6–sialyltransferase.
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parenchyma.
Despite these challenges, potent nonpeptidic small-
molecule BACE1 inhibitors have shown success in 
lowering cerebral Aβ levels in mouse [67-69], hamster 
[70] and primate [71] models. Moreover, the biopharma-
ceutical company CoMentis (South San Francisco, CA, 
USA) recently announced the completion of the ﬁ  rst 
human phase 1 clinical trial of a BACE1 inhibitor drug 
[72]. Other BACE1 inhibitor drug candi  dates will 
probably soon be entering into human clinical trials. An 
interest  ing alternative to small-molecule inhibitors 
entails the use of monoclonal antibodies to inhibit 
BACE1 enzymatic activity. Recent reports hint at the 
potential of antibodies that inhibit BACE1 cleavage of 
APP by either directly binding to BACE1 [73] or by 
binding to the β-secretase cleavage site of APP [74]. Th  e 
latter has shown in vivo eﬃ   cacy for decreasing Aβ in a 
murine model [75]. Th  ese encouraging results suggest 
that therapeutic approaches involving BACE1 inhibition 
for the treatment or prevention of AD may be a reality in 
the future. Given recent data hinting at important 
physiological roles for BACE1, however, careful titration 
of the BACE1 drug dosage may be necessary to minimize 
mechanism-based side eﬀ  ects.
Conclusions
Since the discovery of BACE1 over a decade ago, our 
knowledge about this enzyme has increased signiﬁ  cantly. 
Progress has been made toward the development of 
small-molecule inhibitors capable of penetrating the 
blood–brain barrier and having suﬃ   cient  potency  to 
inhibit Aβ generation in vivo. Th  ere is also very early 
evidence for the prospect of anti-BACE1 monoclonal 
antibodies for AD treatment. Despite promising news of 
BACE1 inhibitor development, however, BACE1 thera-
peutics for routine AD treatment are not yet available. 
Although BACE1 small-molecule inhibitor medicinal 
chemistry and pharmacokinetics have proven challeng-
ing, the recent entry of at least one BACE1 inhibitor into 
clinical trial is an encouraging advance toward BACE1 
therapeutic inhibition for the treatment of AD. Drug-
makers and physicians should keep in mind that BACE1 
appears to have important physiological functions, 
perhaps requiring careful titration of the BACE1 
inhibitor drug dose to minimize potential mechanism-
based toxicity. Finally, advancing our understanding of 
the roles of BACE1 in health and disease will facilitate 
the development of novel therapies for AD and may shed 
light on the etiology of this devastating disease and other 
disorders of the nervous system.
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